Mosquito mitochondrial transfer RNAs for valine, glycine and glutamate: RNA and gene sequences and vicinal genome organization 19851230

1986 ◽  
Vol 10 (9) ◽  
pp. 701-707 ◽  
Author(s):  
Donald T. Dubin ◽  
Chuen-Chin HsuChen ◽  
Lucia E. Tillotson

Author(s):  
Laurence Maréchal-Drouard ◽  
Ian Small ◽  
Anne Cosset ◽  
Anne-Marie Duchêne ◽  
Raman Kumar ◽  
...  




1979 ◽  
Vol 6 (2) ◽  
pp. 455-469 ◽  
Author(s):  
Luke Aujame ◽  
Karl B. Freeman




Biochemistry ◽  
1978 ◽  
Vol 17 (9) ◽  
pp. 1628-1634 ◽  
Author(s):  
Nancy C. Martin ◽  
Murray Rabinowitz


2018 ◽  
Vol 62 (3) ◽  
pp. 467-481 ◽  
Author(s):  
Michio Hirano ◽  
Valentina Emmanuele ◽  
Catarina M. Quinzii

For the vast majority of patients with mitochondrial diseases, only supportive and symptomatic therapies are available. However, in the last decade, due to extraordinary advances in defining the causes and pathomechanisms of these diverse disorders, new therapies are being developed in the laboratory and are entering human clinical trials. In this review, we highlight the current use of dietary supplement and exercise therapies as well as emerging therapies that may be broadly applicable across multiple mitochondrial diseases or tailored for specific disorders. Examples of non-tailored therapeutic targets include: activation of mitochondrial biogenesis, regulation of mitophagy and mitochondrial dynamics, bypass of biochemical defects, mitochondrial replacement therapy, and hypoxia. In contrast, tailored therapies are: scavenging of toxic compounds, deoxynucleoside and deoxynucleotide treatments, cell replacement therapies, gene therapy, shifting mitochondrial DNA mutation heteroplasmy, and stabilization of mutant mitochondrial transfer RNAs.





Cell ◽  
1982 ◽  
Vol 28 (3) ◽  
pp. 543-550 ◽  
Author(s):  
Anita K. Hopper ◽  
Akemi H. Furukawa ◽  
Hung Dinh Pham ◽  
Nancy C. Martin


Sign in / Sign up

Export Citation Format

Share Document